Rifamycins are a class of antibiotics that were first discovered in 1957 and are known for their use in treating tuberculosis (TB). Rifamycins exhibit bactericidal activity against many Gram-positive and Gram-negative bacteria by inhibiting RNA polymerase (RNAP); however, resistance is prevalent and the mechanisms range from primary target modification and antibiotic inactivation to cytoplasmic exclusion. Further, phenotypic resistance, in which only a subpopulation of bacteria grow in concentrations exceeding their minimum inhibitory concentration, and tolerance, which is characterized by reduced rates of bacterial cell death, have been identified as additional causes of rifamycin failure. Here we summarize current understanding and recent developments regarding this critical antibiotic class.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Nature Open Access 30 August 2023
Loss of allosteric regulation in α-isopropylmalate synthase identified as an antimicrobial resistance mechanism
npj Antimicrobials and Resistance Open Access 03 July 2023
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Rinehart KL. Antibiotics with ansa rings. Acc Chem Res. 1972;5:57–64.
Rothstein DM. Rifamycins, alone and in combination. Cold Spring Harb Perspect Med. 2016;6:a027011.
Corpe RF, Sanchez ES. Rifampin in initial treatment of advanced pulmonary tuberculosis. Chest. 1972;61:564–73.
Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis. 2006;43:1468–75.
Newman R, Doster B, Murray FJ, Ferebee S. Rifampin in initial treatment of pulmonary tuberculosis. A U.S. Public Health Service tuberculosis therapy trial. Am Rev Respir Dis. 1971;103:461–76.
Van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis. 2011;52:e194–9.
Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:e1–25.
Zimmerli W, Sendi P. Role of Rifampin against Staphylococcal biofilm infections in vitro, in animal models, and in orthopedic-device-related infections. Antimicrob Agents Chemother. 2019;63:e01746–18.
Baronti A, Lukinovich N. A pilot trial of rifampicin in tuberculosis. Tubercle 1968;49:180–6.
Hyde L. Rifampin in the treatment of pulmonary tuberculosis. Calif Med. 1972;117:18–21.
Vall-Spinosa A, Lester W, Moulding T, Davidson PT, McClatchy JK. Rifampin in the treatment of drug-resistant Mycobacterium tuberculosis infections. N Engl J Med. 1970;283:616–21.
CDC. Tuberculosis data and statistics. 2019. https://www.cdc.gov/tb/statistics/reports/2019/default.htm.
Dickinson JM, Mitchison DA. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle. 1987;68:177–82.
Tam CM, Chan SL, Lam CW, Leung CC, Kam KM, Morris JS, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med. 1998;157:1726–33.
Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353:1843–7.
Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis. 2006;6:710–25.
WHO. Global tuberculosis report 2020. WHO institutional repository for information sharing. 2020. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf.
Sharling L, Marks SM, Goodman M, Chorba T, Mase S. Rifampin-resistant Tuberculosis in the United States, 1998-2014. Clin Infect Dis. 2020;70:1596–605.
Kaur R, Jindal N, Arora S, Kataria S. Epidemiology of rifampicin resistant tuberculosis and common mutations in rpoB gene of Mycobacterium tuberculosis: a retrospective study from six districts of Punjab (India) using Xpert MTB/RIF assay. J Lab Physicians. 2016;8:96–100.
WHO. WHO releases the 2019 AWaRe Classification Antibiotics. (April 20, 2021). 2019. https://www.who.int/publications/i/item/WHOEMPIAU2019.11.
Matteelli A, Rendon A, Tiberi S, Al-Abri S, Voniatis C, Carvalho A, et al. Tuberculosis elimination: where are we now? Eur Respir Rev. 2018;27:180035.
Sensi P. History of the development of Rifampin. Rev Infect Dis. 1983;5:S402–6.
Margalith P, Beretta G. Rifomycin. XI. taxonomic study on Streptomyces mediterranei nov. sp. Mycopathol Mycol Appl. 1960;13:321–30.
Lester W. Rifampin: a semisynthetic derivative of rifamycin–a prototype for the future. Annu Rev Microbiol. 1972;26:85–102.
Margalith P, Pagani H. Rifomycin. XIV. Production of rifomycin B. Appl Microbiol. 1961;9:325–34.
Sensi P, Margalith P. Antibiotic rifamycin b and method of production—US3150046A. 1964. https://patentimages.storage.googleapis.com/ae/cd/00/32617eb19a2b76/US3150046.pdf.
Sensi P, Timbal MT, Maffii G, Rifomycin IX. Two new antibiotics of rifomycin family: rifomycin S and rifomycin SV. Preliminary report. Experientia. 1960;16:412.
Verbist L, Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis. 1968;98:923–32.
Prelog V. Constitution of rifamycins. Pure Appl Chem. 1963;7:551–64.
Riva MA. From milk to rifampicin and back again: history of failures and successes in the treatment for tuberculosis. J Antibiot. 2014;67:661–5.
Bullock WE. Rifampin in the treatment of leprosy. Rev Infect Dis. 1983;5:S606–13.
Bretonnière C, Jozwiak M, Girault C, Beuret P, Trouillet JL, Anguel N, et al. Rifampin use in acute community-acquired meningitis in intensive care units: the French retrospective cohort ACAM-ICU study. Crit Care. 2015;19:303.
Greimel F, Scheuerer C, Gessner A, Simon M, Kalteis T, Grifka J, et al. Efficacy of antibiotic treatment of implant-associated Staphylococcus aureus infections with moxifloxacin, flucloxacillin, rifampin, and combination therapy: an animal study. Drug Des Dev Ther. 2017;11:1729–36.
Sharma L, Losier A, Tolbert T, Dela Cruz CS, Marion CR. Pneumonia updates on legionella, chlamydophila, and mycoplasma pneumonia. Clin Chest Med. 2017;38:45–58.
Karlsen ØE, Borgen P, Bragnes B, Figved W, Grøgaard B, Rydinge J, et al. Rifampin combination therapy in staphylococcal prosthetic joint infections: a randomized controlled trial. J Orthop Surg Res. 2020;15:365.
Renz N, Trampuz A, Zimmerli W. Controversy about the role of rifampin in biofilm infections: is it justified? Antibiotics. 2021;10:165.
Nguyen L. Antibiotic resistance mechanisms in M. tuberculosis: an update. Arch Toxicol. 2016;90:1585–604.
Hong KS, Kim JS. Rifaximin for the treatment of acute infectious diarrhea. Therapeutic Adv Gastroenterol. 2011;4:227–35.
Huang JS, Jiang ZD, Garey KW, Lasco T, DuPont HL. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother. 2013;57:2690–3.
Floss HG, Yu T-W. Rifamycin mode of action, resistance, and biosynthesis. Chem Rev. 2005;105:621–32.
Ghisalba O, Nüesch J. A genetic approach to the biosynthesis of the rifamycin-chromophore in Nocardia mediterranei. IV. Identification of 3-amino-5-hydroxybenzoic acid as a direct precursor of the seven-carbon amino starter-unit. J Antibiot. 1981;34:64–71.
Gygax D, Ghisalba O, Treichler H, Nüesch J. Study to the biosynthesis of the rifamycin-chromophore in Nocardia mediterranei. J Antibiot. 1990;43:324–6.
Floss HG, Yu TW, Arakawa K. The biosynthesis of 3-amino-5-hydroxybenzoic acid (AHBA), the precursor of mC7N units in ansamycin and mitomycin antibiotics: a review. J Antibiot. 2011;64:35–44.
Tang L, Yoon YJ, Choi C-Y, Hutchinson CR. Characterization of the enzymatic domains in the modular polyketide synthase involved in rifamycin B biosynthesis by Amycolatopsis mediterranei. Gene. 1998;216:255–65.
August PR, Tang L, Yoon YJ, Ning S, Müller R, Yu TW, et al. Biosynthesis of the ansamycin antibiotic rifamycin: deductions from the molecular analysis of the rif biosynthetic gene cluster of Amycolatopsis mediterranei S699. Chem Biol. 1998;5:69–79.
Admiraal SJ, Walsh CT, Khosla C. The loading module of rifamycin synthetase is an adenylation–thiolation didomain with substrate tolerance for substituted benzoates. Biochemistry. 2001;40:6116–23.
Yu TW, Shen Y, Doi-Katayama Y, Tang L, Park C, Moore BS, et al. Direct evidence that the rifamycin polyketide synthase assembles polyketide chains processively. Proc Natl Acad Sci USA. 1999;96:9051.LP–6.
Xu J, Wan E, Kim C-J, Floss HG, Mahmud T. Identification of tailoring genes involved in the modification of the polyketide backbone of rifamycin B by Amycolatopsis mediterranei S699. Microbiology. 2005;151:2515–28.
Stratmann A, Schupp T, Toupet C, Schilling W, Oberer L, Traber R. New insights into rifamycin B biosynthesis: isolation of proansamycin B and 34a-Deoxy-rifamycin W as early macrocyclic intermediates indicating two separated biosynthetic pathways. J Antibiot. 2002;55:396–406.
White RJ, Martinelli E, Lancini G. Ansamycin Biogenesis: Studies on a Novel Rifamycin Isolated from a Mutant Strain of Nocardia mediterranei. Proc Natl Acad Sci USA. 1974;71:3260–4.
Ye F, Shi Y, Zhao S, Li Z, Wang H, Lu C, et al. 8-Deoxy-rifamycin derivatives from Amycolatopsis mediterranei S699 ΔrifT strain. Biomolecules. 2020;10:1265.
Xiong Y, Wu X, Mahmud T. A homologue of the Mycobacterium tuberculosis PapA5 Protein, Rif-Orf20, Is an acetyltransferase involved in the biosynthesis of antitubercular drug rifamycin B by Amycolatopsis mediterranei S699. ChemBioChem. 2005;6:834–7.
Xu J, Mahmud T, Floss HG. Isolation and characterization of 27-O-demethylrifamycin SV methyltransferase provides new insights into the post-PKS modification steps during the biosynthesis of the antitubercular drug rifamycin B by Amycolatopsis mediterranei S699. Arch Biochem Biophys. 2003;411:277–88.
Yuan H, Zhao W, Zhong Y, Wang J, Qin Z, Ding X, et al. Two genes, rif15 and rif16, of the rifamycin biosynthetic gene cluster in Amycolatopsis mediterranei likely encode a transketolase and a P450 monooxygenase, respectively, both essential for the conversion of rifamycin SV into B. Acta Biochim Biophys Sin. 2011;43:948–56.
Qi F, Lei C, Li F, Zhang X, Wang J, Zhang W, et al. Deciphering the late steps of rifamycin biosynthesis. Nat Commun. 2018;9:2342.
Bujnowski K, Synoradzki L, Darłak RC, Zevaco TA, Dinjus E. Semi-synthetic zwitterionic rifamycins: a promising class of antibiotics; survey of their chemistry and biological activities. RSC Adv. 2016;6:114758–72.
Baysarowich J, Koteva K, Hughes DW, Ejim L, Griffiths E, Zhang K, et al. Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr. Proc Natl Acad Sci. 2008;105:4886–91.
Peek J, Lilic M, Montiel D, Milshteyn A, Woodworth I, Biggins JB, et al. Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism. Nat Commun. 2018;9:4147.
Wang NJ, Fu Y, Yan GH, Bao GH, Xu CF, He CH. Isolation and structure of a new ansamycin antibiotic kanglemycin A from a Nocardia. J Antibiot. 1988;41:264–7.
Peek J, Xu J, Wang H, Suryavanshi S, Zimmerman M, Russo R, et al. A semisynthetic kanglemycin shows in vivo efficacy against high-burden rifampicin resistant pathogens. ACS Infect Dis. 2020;6:2431–40.
Calvori C, Frontali L, Leoni L, Tecce G. Effect of rifamycin on protein synthesis. Nature. 1965;207:417–8.
Hartmann G, Honikel KO, Knüsel F, Nüesch J. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta. 1967;145:843–4.
Umezawa H, Mizuno S, Yamazaki H, Nitta K. Inhibition of DNA-dependent RNA synthesis by rifamycins. J Antibiot. 1968;21:234–6.
Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104:901–12.
Goldstein BP. Resistance to rifampicin: a review. J Antibiot. 2014;67:625–30.
Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis. 1983;5:S407–11.
Voigt HP, Kaufmann R, Matthaei H. Solubilized DNA-dependent RNA polymerase from human placenta: A Mn(2+)-dependent enzyme. FEBS Lett. 1970;10:257–60.
Furth JJ, Nicholson A, AG E. The enzymatic synthesis of ribonucleic acid in animal tissue: III. Further purification of soluble RNA polymerase from lymphoid tissue and some general properties of the enzyme. Biochim Biophys Acta. 1970;213:124–33.
Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29:1–12.
Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev. 2010;23:14–34.
Phillips I. Clinical uses and control of rifampicin and clindamycin. J Clin Pathol. 1971;24:410–8.
Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–7.
David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20:810–4.
O’Neill AJ, Cove JH, Chopra I. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother. 2001;47:647–50.
Reynolds MG. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics. 2000;156:1471–81.
John AK, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother. 2009;53:2719–24.
Jorgensen NP, Skovdal SM, Meyer RL, Dagnaes-Hansen F, Fuursted K, Petersen E. Rifampicin-containing combinations are superior to combinations of vancomycin, linezolid and daptomycin against Staphylococcus aureus biofilm infection in vivo and in vitro. Pathog Dis 2016;74:ftw019.
Yan Q, Karau MJ, Raval YS, Patel R. Evaluation of oritavancin combinations with rifampin, gentamicin, or linezolid against prosthetic joint infection-associated methicillin-resistant staphylococcus aureus biofilms by time-kill assays. Antimicrob Agents Chemother. 2018;62:e00943–18.
Tang HJ, Chen CC, Cheng KC, Wu KY, Lin YC, Zhang CC, et al. In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013;57:5717–20.
Wehrli W, Knusel F, Schmid K. Interaction of Rifamycin with Bacterial RNA Polymerase. Proc Natl Acad Sci USA. 1968;61:667–73.
Halling SM, Burtis KC, Doi RH. Reconstitution studies show that rifampicin resistance is determined by the largest polypeptide of Bacillus subtilis RNA polymerase. J Biol Chem. 1977;252:9024–31.
Andre E, Goeminne L, Cabibbe A, Beckert P, Kabamba Mukadi B, Mathys V, et al. Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clin Microbiol Infect. 2017;23:167–72.
Bakonyte D, Baranauskaite A, Cicenaite J, Sosnovskaja A, Stakenas P. Mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Lithuania. Int J Tuberculosis Lung Dis Off J Int Union Tuberculosis Lung Dis. 2005;9:936–8.
Jamieson FB, Guthrie JL, Neemuchwala A, Lastovetska O, Melano RG, Mehaffy C. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol. 2014;52:2157–62.
Yue J, Shi W, Xie J, Li Y, Zeng E, Wang H. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China. J Clin Microbiol. 2003;41:2209.LP–12.
Molodtsov V, Scharf NT, Stefan MA, Garcia GA, Murakami KS. Structural basis for rifamycin resistance of bacterial RNA polymerase by the three most clinically important RpoB mutations found in Mycobacterium tuberculosis. Mol Microbiol. 2017;103:1034–45.
Singh A, Grover S, Sinha S, Das M, Somvanshi P, Grover A. Mechanistic principles behind molecular mechanism of rifampicin resistance in mutant RNA polymerase beta subunit of Mycobacterium tuberculosis. J Cell Biochem. 2017;118:4594–606.
Artsimovitch I, Vassylyeva MN, Svetlov D, Svetlov V, Perederina A, Igarashi N, et al. Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell. 2005;122:351–63.
Siu GK, Zhang Y, Lau TC, Lau RW, Ho PL, Yew WW, et al. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis. J Antimicrobial Chemother. 2011;66:730–3.
Khan SN, Niemann S, Gulfraz M, Qayyum M, Siddiqi S, Mirza ZS, et al. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in Punjab, Pakistan. Pak J Zool. 2013;45:93–100.
Prim RI, Schörner MA, Senna SG, Nogueira CL, Figueiredo AC, Oliveira JG, et al. Molecular profiling of drug resistant isolates of Mycobacterium tuberculosis in the state of Santa Catarina, southern Brazil. Mem Inst Oswaldo Cruz. 2015;110:618–23.
Surette MD, Spanogiannopoulos P, Wright GD. The enzymes of the rifamycin antibiotic resistome. Acc Chem Res. 2021;54:2065–75.
Dabbs ER, Yazawa K, Mikami Y, Miyaji M, Morisaki N, Iwasaki S, et al. Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation. Antimicrob Agents Chemother. 1995;39:1007–9.
Shin JH, Eom H, Song WJ, Rho M. Integrative metagenomic and biochemical studies on rifamycin ADP-ribosyltransferases discovered in the sediment microbiome. Sci Rep. 2018;8:12143.
Rominski A, Roditscheff A, Selchow P, Böttger EC, Sander P. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591. J Antimicrobial Chemother. 2017;72:376–84.
Agrawal P, Miryala S, Varshney U. Use of Mycobacterium smegmatis deficient in ADP-ribosyltransferase as surrogate for Mycobacterium tuberculosis in drug testing and mutation analysis. Plos ONE. 2015;10:e0122076.
Tribuddharat C, Fennewald M. Integron-mediated rifampin resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1999;43:960–2.
Arlet G, Nadjar D, Herrmann JL, Donay JL, Lagrange PH, Philippon A. Plasmid-mediated rifampin resistance encoded by an arr-2-like gene cassette in Klebsiella pneumoniae producing an ACC-1 class C beta-lactamase. Antimicrob Agents Chemother. 2001;45:2971–2.
Girlich D, Poirel L, Leelaporn A, Karim A, Tribuddharat C, Fennewald M, et al. Molecular epidemiology of the integron-located VEB-1 extended-spectrum beta-lactamase in nosocomial enterobacterial isolates in Bangkok, Thailand. J Clin Microbiol. 2001;39:175–82.
Spanogiannopoulos P, Waglechner N, Koteva K, Wright GD. A rifamycin inactivating phosphotransferase family shared by environmental and pathogenic bacteria. Proc Natl Acad Sci. 2014;111:7102.LP–7.
Stogios PJ, Cox G, Spanogiannopoulos P, Pillon MC, Waglechner N, Skarina T, et al. Rifampin phosphotransferase is an unusual antibiotic resistance kinase. Nat Commun. 2016;7:11343.
Spanogiannopoulos P, Thaker M, Koteva K, Waglechner N, Wright GD. Characterization of a rifampin-inactivating glycosyltransferase from a screen of environmental actinomycetes. Antimicrobial Agents Chemother. 2012;56:5061.LP–9.
Yazawa K, Mikami Y, Maeda A, Akao M, Morisaki N, Iwasaki S. Inactivation of rifampin by Nocardia brasiliensis. Antimicrob Agents Chemother. 1993;37:1313–7.
Andersen SJ, Quan S, Gowan B, Dabbs ER. Monooxygenase-like sequence of a Rhodococcus equi gene conferring increased resistance to rifampin by inactivating this antibiotic. Antimicrob Agents Chemother. 1997;41:218–21.
Hoshino Y, Fujii S, Shinonaga H, Arai K, Saito F, Fukai T, et al. Monooxygenation of rifampicin catalyzed by the rox gene product of Nocardia farcinica: structure elucidation, gene identification and role in drug resistance. J Antibiot. 2010;63:23–8.
Koteva K, Cox G, Kelso JK, Surette MD, Zubyk HL, Ejim L, et al. Rox, a rifamycin resistance enzyme with an unprecedented mechanism of action. Cell Chem Biol. 2018;25:403–12.e5.
Xu W, DeJesus MA, Rücker N, Engelhart CA, Wright MG, Healy C, et al. Chemical genetic interaction profiling reveals determinants of intrinsic antibiotic resistance in Mycobacterium tuberculosis. Antimicrobial Agents Chemother. 2017;61:e01334–17.
Chandrasekaran S, Lalithakumari D. Plasmid-mediated rifampicin resistance in Pseudomonas fluorescens. J Med Microbiol. 1998;47:197–200.
Zhu JH, Wang BW, Pan M, Zeng YN, Rego H, Javid B. Rifampicin can induce antibiotic tolerance in mycobacteria via paradoxical changes in rpoB transcription. Nat Commun. 2018;9:4218.
Aldridge BB, Keren I, Fortune SM. The spectrum of drug susceptibility in mycobacteria. Microbiol Spectr. 2014;2:MGM2-0031-2013.
Su HW, Zhu JH, Li H, Cai RJ, Ealand C, Wang X, et al. The essential mycobacterial amidotransferase GatCAB is a modulator of specific translational fidelity. Nat Microbiol. 2016;1:16147.
Balaban NQ, Helaine S, Lewis K, Ackermann M, Aldridge B, Andersson DI, et al. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019;17:441–8.
Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019;17:479–96.
El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin Microbiol Rev. 2015;28:191–207.
Javid B, Sorrentino F, Toosky M, Zheng W, Pinkham JT, Jain N, et al. Mycobacterial mistranslation is necessary and sufficient for rifampicin phenotypic resistance. Proc Natl Acad Sci USA. 2014;111:1132–7.
Chaudhuri S, Li L, Zimmerman M, Chen Y, Chen YX, Toosky MN, et al. Kasugamycin potentiates rifampicin and limits emergence of resistance in Mycobacterium tuberculosis by specifically decreasing mycobacterial mistranslation. eLife. 2018;7:e36782.
Cai RJ, Su HW, Li YY, Javid B. Forward genetics reveals a gatC-gatA fusion polypeptide causes mistranslation and rifampicin tolerance in Mycobacterium smegmatis. Front Microbiol. 2020;11:577756.
Brauner A, Fridman O, Gefen O, Balaban NQ. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol. 2016;14:320–30.
Yee R, Cui P, Shi W, Feng J, Zhang Y. Genetic screen reveals the role of purine metabolism in Staphylococcus aureus persistence to rifampicin. Antibiotics. 2015;4:627–42.
Torrey HL, Keren I, Via LE, Lee JS, Lewis K. High persister mutants in Mycobacterium tuberculosis. PloS ONE. 2016;11:e0155127.
Huang X, Duan X, Li J, Niu J, Yuan S, Wang X, et al. The synergistic effect of exogenous glutamine and rifampicin against mycobacterium persisters. Front Microbiol. 2018;9:1625.
Mishra R, Kohli S, Malhotra N, Bandyopadhyay P, Mehta M, Munshi M, et al. Targeting redox heterogeneity to counteract drug tolerance in replicating Mycobacterium tuberculosis. Sci Transl Med. 2019;11:eaaw6635.
Liu Y, Tan S, Huang L, Abramovitch RB, Rohde KH, Zimmerman MD, et al. Immune activation of the host cell induces drug tolerance in Mycobacterium tuberculosis both in vitro and in vivo. J Exp Med. 2016;213:809–25.
Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell. 2011;145:39–53.
Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017;41:276–301.
Ojha AK, Baughn AD, Sambandan D, Hsu T, Trivelli X, Guerardel Y, et al. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol. 2008;69:164–74.
Ealand C, Rimal B, Chang J, Mashigo L, Chengalroyen M, Mapela L, et al. Resuscitation-promoting factors are required for Mycobacterium smegmatis biofilm formation. Appl Environ Microbiol. 2018;84:e00687–18.
Sambandan D, Dao DN, Weinrick BC, Vilchèze C, Gurcha SS, Ojha A, et al. Keto-mycolic acid-dependent pellicle formation confers tolerance to drug-sensitive Mycobacterium tuberculosis. mBio. 2013;4:e00222–13.
Richards JP, Cai W, Zill NA, Zhang W, Ojha AK. Adaptation of Mycobacterium tuberculosis to biofilm growth is genetically linked to drug tolerance. Antimicrob Agents Chemother. 2019;63:e01213–9.
Islam MS, Richards JP, Ojha AK. Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms. Expert Rev Anti Infect Ther. 2012;10:1055–66.
Albano M, Karau MJ, Greenwood-Quaintance KE, Osmon DR, Oravec CP, Berry DJ, et al. In vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against planktonic and biofilm states of staphylococci isolated from periprosthetic joint infection. Antimicrob Agents Chemother. 2019;63:e00959–19.
Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother. 2006;50:55–61.
Sanchez CJ Jr., Shiels SM, Tennent DJ, Hardy SK, Murray CK, Wenke JC. Rifamycin derivatives are effective against staphylococcal biofilms in vitro and elutable from PMMA. Clin Orthop Relat Res. 2015;473:2874–84.
Singh R, Barry CE, Boshoff HIM. The three RelE homologs of Mycobacterium tuberculosis have individual, drug-specific effects on bacterial antibiotic tolerance. J Bacteriol. 2010;192:1279–91.
Fishbein SRS, Tomasi FG, Wolf ID, Dulberger CL, Wang A, Keshishian H, et al. The conserved translation factor LepA is required for optimal synthesis of a porin family in Mycobacterium smegmatis. J Bacteriol. 2020;203:e00604–20.
Rego EH, Audette RE, Rubin EJ. Deletion of a mycobacterial divisome factor collapses single-cell phenotypic heterogeneity. Nature. 2017;546:153–7.
Wang B-W, Zhu J-H, Javid B. Clinically relevant mutations in mycobacterial LepA cause rifampicin-specific phenotypic resistance. Sci Rep. 2020;10:8402.
Riva S, Silvestri LG. Rifamycins: a general view. Annu Rev Microbiol. 1972;26:199–224.
This work was supported by the 250th Anniversary Fund for Innovation in Undergraduate Education, the Program for Community Engaged Scholarship, and the Council on Science and Technology at Princeton University (MPB). This content is solely the responsibility of the authors and does not necessarily represent the views of the funding agencies.
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Adams, R.A., Leon, G., Miller, N.M. et al. Rifamycin antibiotics and the mechanisms of their failure. J Antibiot 74, 786–798 (2021). https://doi.org/10.1038/s41429-021-00462-x
This article is cited by
Loss of allosteric regulation in α-isopropylmalate synthase identified as an antimicrobial resistance mechanism
npj Antimicrobials and Resistance (2023)
Characteristics of antibiotic resistance gene distribution in rainfall runoff and combined sewer overflow
Environmental Science and Pollution Research (2022)
Nature Microbiology (2021)